Aminopyrrolic Synthetic Receptors for Monosaccharides
FULL PAPER
thetic Receptors (Eds.: T. Schrader, A. D. Hamilton), Wiley-VCH,
Weinheim, 2005, pp. 45–109.
volved in the process at some stage, possibly facilitating
the approach of the inhibitor and its permeation through
the cell wall.
3) By following, through fluorescence microscopy, the fate
of the inhibitors when incubated with the microorgan-
isms it was found that aminopyrrolic compounds were in-
ternalized into the cytoplasm, whereas the corresponding
structures devoid of pyrrolic groups did not pass through
the cell wall. While supporting the previous conclusion,
this evidence indicates that pyrrolic groups are required
for inhibitor permeability.
4) The toxicity of this family of inhibitors parallels their an-
tibiotic activity, in that the most active compounds are
also the most toxic toward human hepatocytes. However,
the toxicity of the most effective inhibitors is comparable
to that of amphotericin B and ketoconazole.
5) Localization experiments through fluorescence microsco-
py on human hepatocytes showed that both the (inac-
tive) amino- and the (active) aminopyrrolic compounds
were internalized into the cytoplasm, which demonstrat-
ed that pyrrolic groups are responsible not only for the
permeability, but also for the antibiotic activity and tox-
icity of the inhibitors. Furthermore, this evidence reinfor-
ces the hypothesis that inhibitor permeation mediated by
carbohydrate recognition on the cell wall of yeasts is
a crucial step of a cascade of events responsible for the
antibiotic activity of these compounds.
[6] S.-K. Wang, P.-H. Liang, R. D. Astronomo, T.-L. Hsu, S.-L. Hsieh,
[7] a) Y. Nakagawa, Y. Masuda, K. Yamada, T. Doi, K. Takegoshi, Y.
T. Hiratami, S. Inoue, S. Kondo, T. Takeuchi, H. Yamaguchi, J. Anti-
[8] a) J. Balzarini, K. Van Laethem, D. Daelemans, S. Hatse, A. Bugatti,
373; b) A. Tanabe-Tochikura, T. S. Tochikura, O. Yoshida, T. Oki, N.
[9] S. Shahzad-ul-Hussan, E. Gustchina, R. Ghirlando, G. M. Clore,
[10] a) C. Nativi, O. Francesconi, G. Gabrielli, A. Vacca, S. Roelens,
Nativi, O. Francesconi, G. Gabrielli, A. Ienco, J. Jimꢅnez-Barbero, S.
Roelens, Chem. Eur. J. 2011, 17, 4821–4829; c) A. Ardꢄ, C. Venturi,
C. Nativi, O. Francesconi, G. Gabrielli, F. J. CaÇada, J. Jimꢅnez-Bar-
bero, S. Roelens, Chem. Eur. J. 2010, 16, 414–418; d) C. Nativi, M.
4685–4688; e) C. Nativi, M. Cacciarini, O. Francesconi, A. Vacca, G.
[12] C. R. Cooper Jr., in The Yeasts: A Taxonomic Study, Vol. 1, 5th ed.
(Eds.: C. P. Kurtzman, J. W. Fell, T. Boekhout), Elsevier Science,
Amsterdam, 2011, pp. 9–19.
As a closing remark, quoting from the recent ACS Webi-
nar on the future of antimicrobial drug discovery: “Antimi-
crobial resistance is growing at an alarming rate and The In-
fectious Disease Society of America has issued the challenge
to develop ten new antibiotics by 2020. How difficult will
this be? What are the hurdles?”. In this context, it appears
that the aminopyrrolic inhibitors of yeast and yeast-like pro-
liferation presented in this paper may constitute a new tool
against pathogenic microorganisms and may have an impact
on the development of new drugs circumventing antibiotic
resistance.
[13] Among these yeasts (labeled as emerging pathogens), the literature
reports cases of cutaneous or systemic mycoses mainly caused by
strains of Candida glabrata, Meyerozyma guilliermondii (teleomor-
phic state of Candida guilliermondii), Pichia kudriavzevii (teleomor-
phic state of Candida krusei), Pichia norvegensis (former Candida
zeylanoides), and Clavispora lusitaniae, see: a) M. A. Lachance in
The Yeasts: A Taxonomic Study, Vol. 2, 5th ed. (Eds.: C. P. Kurtz-
man, J. W. Fell, T. Boekhout), Elsevier Science, Amsterdam, 2011,
pp. 349–353; b) C. P. Kurtzman in The Yeasts: A Taxonomic Study,
Vol. 2, 5th ed. (Eds.: C. P. Kurtzman, J. W. Fell, T. Boekhout), Elsev-
ier Science, Amsterdam, 2011, pp. 685–707; c) R. S. Pore in The
Yeasts: A Taxonomic Study, Vol. 3, 5th ed. (Eds.: C. P. Kurtzman,
J. W. Fell, T. Boekhout), Elsevier Science, Amsterdam, 2011,
pp. 2071–2080.
Acknowledgements
A research grant to Dr. Oscar Francesconi (grant no. 2008.1475) from
Ente Cassa di Risparmio di Firenze is gratefully acknowledged.
[14] U. Roesler, A. Mçller, A. Hensel, D. Baumann, U. Truyen, Int. J.
[15] The BC50 (median binding concentration) parameter, which can be
calculated from the measured association constants, is a generalized
affinity descriptor univocally defining on a common scale the overall
binding ability of receptors for ligands in chemical systems involving
any number of complex species. The BC50 is defined as the total con-
centration of receptor necessary for binding 50% of the ligand and
directly provides a quantitative measure of binding ability as, in
analogy to the IC50 parameter, the lower the value, the higher the
affinity. The BC050 (intrinsic median binding concentration) is the
value assumed by the BC50 when the fraction of bound receptor is
zero, that is, when forming the first complex molecule; this is a re-
ceptor specific constant value, independent of concentration, which
coincides with the dissociation constant Kd when the 1:1 association
is the only equilibrium present in solution. A detailed description of
the treatment of the BC50 descriptor has been reported (see referen-
[1] a) The Sugar Code: Fundamentals of Glycosciences (Ed.: H.-J.
Gabius), Wiley-VCH, Weinheim, 2009; b) B. Ernst, W. Hart, P.
Sinaꢃ, Carbohydrates in Chemistry and Biology, Part I.2 and
Part II.4, Wiley-VCH, Weinheim, 2000; c) T. K. Lindhorst, Essentials
of Carbohydrate Chemistry and Biochemistry, 1st ed., Wiley-VCH,
Weinheim, 2000.
[3] a) C. N. Scanlan, J. Offer, N. Zitzmann, R. A. Dwek, Nature 2007,
[4] a) S. Jin, Y. Cheng, S. Reid, M. Li, B. Wang, Med. Res. Rev. 2010, 30,
Chem. Eur. J. 2012, 18, 5064 – 5072
ꢁ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
5071